Atlas Trials

Study to Evaluate Efficacy and Safety of BGB-3111 in Participants With Relapsed or Refractory Mantle Cell Lymphoma (MCL)

Clinical trial NCT03206970 · COMPLETED

Trial details

NCT number
NCT03206970
Sponsor
BeiGene
Status
COMPLETED
Phase
Phase 2
Study type
INTERVENTIONAL
Refractory Mantle Cell LymphomaRelapsed Mantle Cell Lymphoma
Start date
2017-03-02
Primary completion
2019-02-15
Enrollment
86

View on ClinicalTrials.gov

Track trials programmatically

Sponsors, conditions and status changes through the Atlas API.